Expertise in
15
conditions

Dr. Divaya Bhutani

Internal Medicine
CUIMC/Herbert Irving Pavilion
161 Fort Washington Ave, 
New York, NY 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth
Before you request
Expertise in
15
conditions
CUIMC/Herbert Irving Pavilion
161 Fort Washington Ave, 
New York, NY 

Overview

Divaya Bhutani is a primary care provider, practicing in Internal Medicine in New York, New York.

Dr. Bhutani is highly rated in 15 conditions, according to our data. His clinical expertise encompasses Multiple Myeloma, Smoldering Multiple Myeloma, Primary Amyloidosis, Relapsed Refractory Multiple Myeloma (RRMM), and Bone Marrow Aspiration.

He is actively involved in clinical research, co-authoring 80 peer reviewed articles and participating in 12 clinical trials. Dr. Bhutani is currently accepting new patients.

Specialties

Internal Medicine

Licenses

Internal Medicine in MI

Hospital Affiliations

New York-Presbyterian Hospital

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Health First
  • HMO
  • POS
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
McLaren Health
  • HMO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
MetroPlus Health
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE-MEDICAID PLAN
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
VNS Health
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 9 Less Insurance Carriers -

Locations

CUIMC/Herbert Irving Pavilion
161 Fort Washington Ave, New York, NY 10032

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

12 Clinical Trials

A Phase II Randomized Study Comparing BTK Inhibitors (Ibrutinib Plus Rituximab or Zanubrutinib Alone) vs. BCL-2 Inhibitor (Venetoclax) and Rituximab in Previously Untreated Waldenström's Macroglobulinemia (WM) / Lymphoplasmacytic Lymphoma (LPL)
A Phase II Randomized Study Comparing BTK Inhibitors (Ibrutinib Plus Rituximab or Zanubrutinib Alone) vs. BCL-2 Inhibitor (Venetoclax) and Rituximab in Previously Untreated Waldenström's Macroglobulinemia (WM) / Lymphoplasmacytic Lymphoma (LPL)
Enrollment Status: Recruiting
Publish Date: July 29, 2026
Intervention Type: Biological, Procedure, Drug
Study Drugs: Ibrutinib, Rituximab, Venetoclax
Study Phase: Phase 2
Randomized Phase III Trial of Lenalidomide Versus Observation Alone in Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma
Randomized Phase III Trial of Lenalidomide Versus Observation Alone in Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma
Enrollment Status: Active_not_recruiting
Publish Date: August 04, 2026
Intervention Type: Other, Drug
Study Drug: Lenalidomide
Study Phase: Phase 3
Randomized Phase 2 Trial of Isatuximab During Autologous Stem Cell Collection and Transplantation Period in Patients With Multiple Myeloma, Relapsed Hodgkin's and Non-Hodgkin's Lymphoma
Randomized Phase 2 Trial of Isatuximab During Autologous Stem Cell Collection and Transplantation Period in Patients With Multiple Myeloma, Relapsed Hodgkin's and Non-Hodgkin's Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: July 23, 2026
Intervention Type: Other, Drug
Study Phase: Phase 2
A Single Arm, Multicenter, Phase II, Open-Label Trial to Evaluate Efficacy of Isatuximab in Patients With Monoclonal Gammopathy of Renal Significance
A Single Arm, Multicenter, Phase II, Open-Label Trial to Evaluate Efficacy of Isatuximab in Patients With Monoclonal Gammopathy of Renal Significance
Enrollment Status: Active_not_recruiting
Publish Date: July 23, 2026
Intervention Type: Drug
Study Drug: Isatuximab
Study Phase: Phase 2
A Phase 1b/2 Investigator Initiated Study of RCHOP in Combination With Selinexor (KPT-330) in B Cell Non-Hodgkin's Lymphoma
A Phase 1b/2 Investigator Initiated Study of RCHOP in Combination With Selinexor (KPT-330) in B Cell Non-Hodgkin's Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: September 29, 2025
Intervention Type: Drug
Study Drug: Selinexor
Study Phase: Phase 1/Phase 2
A Multi-Center, Phase II Trial of HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide for Patients With Hematologic Malignancies
A Multi-Center, Phase II Trial of HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide for Patients With Hematologic Malignancies
Enrollment Status: Completed
Publish Date: August 06, 2025
Intervention Type: Drug, Radiation, Procedure
Study Phase: Phase 2
A Phase II Multicenter Single Arm Study to Evaluate the Efficacy and Safety of Single Agent Bruton's Tyrosine Kinase Inhibitor, Ibrutinib, in Patients With Relapsed Refractory Classical Hodgkin's Lymphoma
A Phase II Multicenter Single Arm Study to Evaluate the Efficacy and Safety of Single Agent Bruton's Tyrosine Kinase Inhibitor, Ibrutinib, in Patients With Relapsed Refractory Classical Hodgkin's Lymphoma
Enrollment Status: Completed
Publish Date: February 17, 2025
Intervention Type: Drug, Other
Study Drug: Ibrutinib
Study Phase: Phase 2
E- PRISM: Precision Intervention Smoldering Myeloma: Phase II Trial of Combination of Elotuzumab, Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple Myeloma
E- PRISM: Precision Intervention Smoldering Myeloma: Phase II Trial of Combination of Elotuzumab, Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple Myeloma
Enrollment Status: Completed
Publish Date: June 09, 2023
Intervention Type: Drug
Study Drugs: Elotuzumab, Lenalidomide, Dexamethasone
Study Phase: Phase 2
A Phase 1 Study to Evaluate the Safety, Proliferation and Persistence of GEN-011, an Autologous Adoptive Cell Therapy Targeting Neoantigens in Solid Tumors
A Phase 1 Study to Evaluate the Safety, Proliferation and Persistence of GEN-011, an Autologous Adoptive Cell Therapy Targeting Neoantigens in Solid Tumors
Enrollment Status: Terminated
Publish Date: July 15, 2022
Intervention Type: Drug, Biological
Study Drugs: IL-2, Fludarabine, Cyclophosphamide
Study Phase: Phase 1
Phase I Study of Dasatinib in Recipients of Allogeneic Stem Cell Transplantation for Hematologic Malignancies.
Phase I Study of Dasatinib in Recipients of Allogeneic Stem Cell Transplantation for Hematologic Malignancies.
Enrollment Status: Terminated
Publish Date: December 17, 2020
Intervention Type: Other, Drug
Study Phase: Phase 1
View 9 Less Clinical Trials

80 Total Publications

Erratum: Efficacy and Safety of Anselamimab in Immunoglobulin Light Chain Amyloidosis: Results From the Randomized CARES Trials.
Erratum: Efficacy and Safety of Anselamimab in Immunoglobulin Light Chain Amyloidosis: Results From the Randomized CARES Trials.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: August 03, 2026
Similar Doctors
Expertise in
39
conditions
Dr. Mark G. Lebwohl
Internal Medicine
Expertise in
39
conditions
Dr. Mark G. Lebwohl
Internal Medicine
Before you request

Icahn School Of Medicine At Mount Sinai

5 E 98th St, 
New York, NY 
 (3.6 miles away)
212-241-9728
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Mark Lebwohl is a primary care provider, practicing in Internal Medicine in New York, New York. Dr. Lebwohl is highly rated in 39 conditions, according to our data. His clinical expertise encompasses Plaque Psoriasis, Psoriasis, Pustular Psoriasis, and Generalized Pustular Psoriasis (GPP). Dr. Lebwohl is currently accepting new patients.

Expertise in
14
conditions
Dr. John P. Bilezikian
Internal Medicine
Expertise in
14
conditions
Dr. John P. Bilezikian
Internal Medicine
Before you request

NewYork Presbyterian Columbia University Irving Medical Center

180 Fort Washington Ave, 
New York, NY 
 (0.1 miles away)
212-305-2663
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

John Bilezikian is a primary care provider, practicing in Internal Medicine in New York, New York. Dr. Bilezikian is highly rated in 14 conditions, according to our data. His clinical expertise encompasses Hypoparathyroidism, Hypercalcemia, Milk-Alkali Syndrome, Parathyroidectomy, and Hormone Replacement Therapy (HRT). Dr. Bilezikian is currently accepting new patients.

Expertise in
13
conditions
Dr. Ryan C. Ungaro
Internal Medicine
Expertise in
13
conditions
Dr. Ryan C. Ungaro
Internal Medicine

MSSM-Optical Shop

17 E 102nd St, 
New York, NY 
 (3.4 miles away)
212-241-8100
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Ryan Ungaro is a primary care provider, practicing in Internal Medicine in New York, New York. Dr. Ungaro is highly rated in 13 conditions, according to our data. His clinical expertise encompasses Crohn's Disease, Viral Gastroenteritis, Ulcerative Colitis, Colonoscopy, and Endoscopy.

Frequently Asked Questions about Dr. Divaya Bhutani

How do I make an appointment with Dr. Divaya Bhutani?

You can book an appointment with Dr. Divaya Bhutani by calling their office at 914-573-5582. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Divaya Bhutani a top-rated expert for Multiple Myeloma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Divaya Bhutani is classified as an Elite expert for Multiple Myeloma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Divaya Bhutani specialize in?

While Dr. Divaya Bhutani is a Internal Medicine, they have specific expertise in Multiple Myeloma, Smoldering Multiple Myeloma, and Primary Amyloidosis. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Internal Medicine.

Does Dr. Divaya Bhutani participate in research or clinical trials?

Yes. Dr. Divaya Bhutani has published 80 articles and abstracts on conditions like Multiple Myeloma. You can view a list of Dr. Divaya Bhutani's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Divaya Bhutani accept my insurance?

Dr. Divaya Bhutani accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 914-573-5582 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Bhutani's expertise for a condition
ConditionClose
View All 10 Advanced Conditions
View All 70 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile